Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
7 stopped studies mapped to Non-Muscle Invasive Bladder Carcinoma and descendants · 100% state a reason
Over the 7 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05014139 | A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle… | Phase 1 | terminated | Aug 20, 2021 | Astellas Pharma Global Development, Inc. | Trial was discontinued for strategic reasons. Decision was not based on safety concerns, futility,… | Safety / toxicity |
| NCT02106572 | Therapeutic Instillation of Mistletoe(TIM) | Phase 3 | terminated | Apr 8, 2014 | Abnoba Gmbh | The study was terminated because the required number of patients cannot be reached in the… | Safety / toxicity |
| NCT07551544 | ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed… | Phase 3 | withdrawn | Apr 27, 2026 | ImmunityBio, Inc. | Sponsor decision | Sponsor / business decision |
| NCT06069453 | Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC. | N/A | terminated | Oct 5, 2023 | Fidia Farmaceutici s.p.a. | Sponsor decision | Sponsor / business decision |
| NCT03839472 | Continuous Bladder Irrigation Following Transurethral Resection of Bladder Tumors | N/A | withdrawn | Feb 15, 2019 | Case Comprehensive Cancer Center | Revision to improve cell recovery | Other (stated, no rule matched) |
| NCT03719300 | Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC | Phase 2 | terminated | Oct 25, 2018 | Anchiano Therapeutics Israel Ltd. | Lack of efficacy | Efficacy / futility |
| NCT03167151 | Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla) | Phase 1 / Phase 2 | terminated | May 25, 2017 | University of Oxford | The study failed to recruit within the permitted timeframe | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials